Breakthrough BiTS Therapy Offers Targeted Hope for Autoimmune Diseases, With Implications for Thailand
A new international study outlines a potential breakthrough for autoimmune conditions, including type 1 diabetes. Researchers describe BiTS, a protein-based therapy that may halt disease progression by precisely silencing problematic T cells. The work, conducted across institutions in New York, China, and Zhejiang, demonstrates in animal models how targeted immune suppression can curb disease while preserving overall immunity.
The findings resonate with Thailand, where autoimmune diseases are placing a growing burden on patients and families who depend on long-term medications. Autoimmune conditions occur when the immune system mistakenly attacks healthy tissues. Current treatments mainly control symptoms and carry notable side effects, underscoring the need for therapies that address root causes.
